[go: up one dir, main page]

AR057904A1 - Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide - Google Patents

Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide

Info

Publication number
AR057904A1
AR057904A1 ARP060105052A ARP060105052A AR057904A1 AR 057904 A1 AR057904 A1 AR 057904A1 AR P060105052 A ARP060105052 A AR P060105052A AR P060105052 A ARP060105052 A AR P060105052A AR 057904 A1 AR057904 A1 AR 057904A1
Authority
AR
Argentina
Prior art keywords
medications
agent
corticoesteroid
antimuscerinic
inflammatory
Prior art date
Application number
ARP060105052A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35580403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057904(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR057904A1 publication Critical patent/AR057904A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Medicamentos que comprenden (A) un agente antimuscarínico y (B) un corticoesteroide, para el tratamiento de enfermedades inflamatorias u obstructivas de las vías respiratorias. Reivindicacion 1: Un medicamento que comprende, en forma separada o en conjunto, (A) una sal de glicopirronio y (B) un compuesto de la formula (1) en donde T es un grupo orgánico cíclico monovalente que tiene de 3 a 15 átomos en el sistema de anillo,. para administracion simultánea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de las vías respiratorias.
ARP060105052A 2005-11-21 2006-11-17 Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide AR057904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0523654.2A GB0523654D0 (en) 2005-11-21 2005-11-21 Organic compounds

Publications (1)

Publication Number Publication Date
AR057904A1 true AR057904A1 (es) 2007-12-26

Family

ID=35580403

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105052A AR057904A1 (es) 2005-11-21 2006-11-17 Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide

Country Status (14)

Country Link
US (1) US20080274189A1 (es)
EP (1) EP1954267A1 (es)
JP (1) JP2009516663A (es)
KR (1) KR20080069194A (es)
CN (1) CN101309684A (es)
AR (1) AR057904A1 (es)
AU (1) AU2006314724A1 (es)
BR (1) BRPI0618786A2 (es)
CA (1) CA2628172A1 (es)
GB (1) GB0523654D0 (es)
PE (1) PE20070828A1 (es)
RU (1) RU2008124836A (es)
TW (1) TW200803841A (es)
WO (1) WO2007057223A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PT2230934E (pt) 2007-12-14 2012-11-20 Aerodesigns Inc Distribuir produtos alimentares aerossolizáveis
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL2435024T3 (pl) * 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CA2935305C (en) 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3191081B1 (en) 2014-09-09 2020-03-25 Vectura Limited Formulation comprising glycopyrrolate, method and apparatus
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
KR102835735B1 (ko) 2019-12-02 2025-07-21 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0217504D0 (en) * 2002-07-29 2002-09-04 Novartis Ag Organic compounds
DK1713473T3 (da) * 2004-02-06 2013-06-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og glucocorticoider til langtidsbehandling af astma og COPD
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease

Also Published As

Publication number Publication date
JP2009516663A (ja) 2009-04-23
WO2007057223A1 (en) 2007-05-24
TW200803841A (en) 2008-01-16
GB0523654D0 (en) 2005-12-28
BRPI0618786A2 (pt) 2011-09-13
RU2008124836A (ru) 2009-12-27
KR20080069194A (ko) 2008-07-25
CN101309684A (zh) 2008-11-19
CA2628172A1 (en) 2007-05-24
EP1954267A1 (en) 2008-08-13
PE20070828A1 (es) 2007-09-05
US20080274189A1 (en) 2008-11-06
AU2006314724A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
ECSP034620A (es) Mezclas o compuestos organicos para el tratamiento de enfermedades de las vias respiratorias
AR062584A1 (es) Medicamentos para tratar enfermedades de las vias respiratorias
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR109590A2 (es) Régimen posológico para inhibidores de comt
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
AR057904A1 (es) Medicamentos que comprenden un agente antimuscerinico y un corticoesteroide
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
ATE513562T1 (de) Nicht-spezifische immunstimulierende mittel
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
BRPI0411451A (pt) formas de dosagens orais de memantina
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
MX2009005798A (es) Recuperacion de apoplejia.
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
BR112014007684A2 (pt) tratamento da rinite
Farallo et al. Nephrotic syndrome after treatment with d-penicillamine in a pediatric patient with Wilson’ s disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal